Ceftazidime with β-lactamase inhibitor approved for complicated infections.

FDA and Actavis plc on February 26 announced the approval of the antibacterial product ceftazidime–avibactam, or Avycaz, for the treatment of adults with complicated intraabdominal and urinary tract infections caused by certain bacteria. The agency said its decision to approve Avycaz was made on